A clear refocused investment strategy and increased conviction in our ability to demonstrate significant shareholder value progression.

Our Board of Directors has collective responsibility for the long-term success of Vectura. Following our successful merger with Skyepharma, the Board has been working to ensure that we have effective, entrepreneurial and prudent management for the long-term success of the business and that our governance for the enlarged Group facilitates that.

Compliance with the UK Governance Code

Further information regarding our governance at Vectura can be found in our Report and Accounts for the year ended 31 December 2019 available here.

Schedule of Matters Reserved for the Board

The Audit Committee terms of reference

The Nomination Committee terms of reference

The Remuneration Committee terms of reference

Remuneration Policy approved 2020

Articles of Association

2018 AGM Votes – Advisory note

Statement under s.430(2B) Companies Act 2006

View a copy of the Modern Slavery Statement